Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn’s disease

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 11, 2016, Pages 1321-1325

  Kadir, Sara Irini ^a   Wenzel Kragstrup, Tue ^b   Dige, Anders ^a   Kok Jensen, Simon ^b   Dahlerup, Jens Frederik ^a   Kelsen, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Crohn s disease; fibrosis; pirfenidone

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AZATHIOPRINE; COLLAGEN; METHOTREXATE; PIRFENIDONE; STROMELYSIN; THY 1 ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ACTA2 PROTEIN, HUMAN; ACTIN; MMP3 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; TIMP1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CALORIMETRY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLINICAL ARTICLE; COLON MUCOSA; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TURNOVER TIME; CELL CULTURE; CYTOLOGY; DENMARK; DRUG EFFECTS; ENDOSCOPY; FIBROSIS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; STATISTICAL MODEL;

ACTINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CROHN DISEASE; DENMARK; ENDOSCOPY; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; INTESTINAL MUCOSA; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 3; PYRIDONES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84967167030     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2016.1185146     Document Type: Article

References (21)

1. J.P.Burke, J.J.Mulsow, C.O'Keane,. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439–448.
2. E.Louis, A.Collard, A.F.Oger,. Behaviour of Crohn's disease according to the Vienna classification:changing pattern over the course of the disease. Gut. 2001;49:777–782.
3. F.Rieder, C.Fiocchi Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis. 2013;31:186–193.
4. G.Rogler New therapeutic avenues for treatment of fibrosis:can we learn from other diseases? Dig Dis. 2014;32:39–49.
5. G.Latella, R.Sferra, S.Speca,. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17:1283–1304.
6. G.Latella, G.Rogler, G.Bamias,. Results of the 4th scientific workshop of the ECCO (I):pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014;8:1147–1165.
7. A.Di Sabatino, C.L.Jackson, K.M.Pickard,. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777–789.
8. C.J.Schaefer, D.W.Ruhrmund, L.Pan,. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85–97.
9. F.Rieder, C.Fiocchi Intestinal fibrosis in inflammatory bowel disease – current knowledge and future perspectives. J Crohns Colitis. 2008;2:279–290.
10. J.Armendariz-Borunda, M.C.Islas-Carbajal, E.Meza-Garcia,. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2006;55:1663–1665.
11. V.Cottin, T.Maher Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24:58–64.
12. J.Macias-Barragan, A.Sandoval-Rodriguez, J.Navarro-Partida,. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16–27.
13. E.Pesce, E.Struma, S.N.Giri,. Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans. Res Comm Mol Pathol Pharmacol. 2004;115-116:39–48.
14. J.Armendariz-Borunda, I.Lyra-Gonzalez, D.Medina-Preciado,. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 2012;68:22–28.
15. K.J.Grattendick, J.M.Nakashima, L.Feng,. Effects of three anti-TNF-alpha drugs:etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol. 2008;8:679–687.
16. F.Rieder, J.R.de Bruyn, B.T.Pham,. Results of the 4th scientific workshop of the ECCO (Group II):markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166–1178.
17. A.Dignass, G.Van Assche, J.O.Lindsay,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease:current management. J Crohns Colitis. 2010;4:28–62.
18. W.R.Best, J.M.Becktel, J.W.SingletonJr,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439–444.
19. W.R.Best Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamma Bowel Dis. 2006;12:304–310.
20. Q.Shi, X.Liu, Y.Bai,. In vitro effects of pirfenidone on cardiac fibroblasts:proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One. 2011;6:e28134. DOI:10.1371/journal.pone.0028134.
21. L.Makitalo, T.Sipponen, P.Karkkainen,. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis. 2009;24:1157–1167.